Why CHR works with just 2 insurance companies, curing embryos of genetic diseases, & more – September 2017 CHR VOICE Digest

After the VOICE took only a one-month hiatus in August, and with the summer almost behind us, we welcome back all of our readers to the 2017/2018 academic year. What a year it has been so far! We finally completed over two years of construction, which resulted in a brand-new, states-of-the-arts IVF unit as well as expanded research and conference facilities. Less visible, nursing and administrative staffs now have significantly more work space. Construction even netted us a large roof-top terrace on top of the new expansion building, which can be used for outdoor conferences or just social gatherings.

Eighteen in PubMed-listed peer-reviewed publications by the year’s half point on July 1, was also a new CHR record, reflecting on the center’s expanding research and publication efforts  (more on that below).

With lots of vacation time taken during July and August, the remaining staff was kept busy. Our administration was especially busy because it had to manage the very final stages of the construction effort, including many internal moves into completed spaces.

As a co-sponsor of the annual Foundation for Reproductive Medicine Conference on Translational Reproductive Biology and Clinical Reproductive Endocrinology, which this year will again take place on November 16-19 at the Grand Hyatt Hotel New York, preparations went into high gear. With almost double the abstract submissions of last year’s conference, we expect record attendance. We also expect record attendance because of the rather amazing faculty the conference was able to attract for this year (for more on that, see also below).

Expecting many more good things to happen, we are with great anticipation looking forward toward the second half of 2017. As is our practice, this issue of the VOICE will again report on exciting new developments in reproductive medicine, with the potential for truly revolutionary progress coming closer and closer in treatment of infertility and avoidance of genetic inheritance of diseases.

The summer months also saw some interesting new developments relating to subjects we have dedicated in these pages considerable space to over the last year. To our considerable pleasure, regarding preimplantation genetic screening (PGS) and the use of nuclear transfer techniques, as we will explain in much more detail below, those developments have been very supportive of longstanding opinions expressed by CHR.

In some cultures, living in “exciting times” is considered a curse; in science, that is definitely not the case. We love to live in exiting times! For the rest of the year 2017 we, therefore, hope for much more exciting times in science and, maybe, a little less so in domestic and international politics.

In this issue, we cover:

Read the September 2017 VOICE in a PDF

Norbert Gleicher, MD, leads CHR’s clinical and research efforts as Medical Director and Chief Scientist. A world-renowned reproductive endocrinologist, Dr. Gleicher has published hundreds of peer-reviewed papers and lectured globally while keeping an active clinical career focused on ovarian aging, immunological issues and other difficult cases of infertility.